Respiratory Lab Software Vendor Landscape UK 2026: An Independent Comparison of Sleep Reporting Platforms Available to NHS Trusts

Feb 20, 2026

NHS Trusts selecting respiratory and sleep lab software in 2026 face a market that is growing rapidly but remains poorly served by genuinely purpose-built solutions. Most platforms available to UK clinical physiology labs were either designed for broader diagnostic use cases, built on ageing on-premise architecture, or developed by device manufacturers with an inherent interest in locking labs to their own hardware. This guide maps the current vendor landscape, identifies what NHS labs should actually be evaluating, and explains why the distinction between manufacturer-built and independent platforms matters more than most procurement teams realise.

TL;DR

  • The UK respiratory diagnostics software market sits within a global sector projected to grow significantly through 2033, but clinical-grade sleep and respiratory reporting tools remain a niche category with few specialist vendors.

  • NHS Trusts should prioritise vendor-neutral, cloud-based platforms that eliminate double data entry, support ATS-aligned reporting, and integrate with existing PAS and EMR systems.

  • Manufacturer-tied software creates long-term procurement risk; independent platforms offer genuine device agnosticism.

  • Switching from legacy systems is more straightforward than most labs expect, particularly when the new platform offers structured data migration support.

  • Rezibase is one of the few platforms purpose-built by respiratory scientists, currently active in NHS Trusts and designed around real clinical physiology workflows.

Why Is the UK Respiratory Lab Software Market Growing in 2026?

The respiratory diagnostics sector is expanding at pace. According to SkyQuest, the global respiratory disease testing market was valued at USD 8.46 billion in 2024 and is projected to reach USD 17.64 billion by 2033. Grand View Research places the infectious respiratory disease diagnostics market at USD 12.56 billion in 2025, forecast to reach USD 15.70 billion by 2033 at a CAGR of 2.90%.

In the United States, Mordor Intelligence reports the respiratory devices market is worth USD 10.24 billion in 2026, growing at a CAGR of 5.05% toward USD 13.11 billion by 2031. The UK market mirrors these dynamics, shaped by:

  • Rising COPD and sleep-disordered breathing prevalence

  • Post-COVID demand for pulmonary function and long COVID diagnostics

  • NHS digital transformation programmes pushing labs toward cloud-based workflows

  • The UK Government's Life Sciences Sector Plan, published in 2025, which explicitly targets investment in health technology scaling and digital infrastructure

This growth creates both opportunity and noise. More vendors are entering the space, but not all of them understand clinical physiology workflows.

What Should NHS Trusts Actually Evaluate in a Sleep Reporting Platform?

Most procurement checklists focus on features. The more important question is: was this software built by people who have actually run a respiratory lab?

The gap between a generic diagnostic platform and a purpose-built respiratory and sleep reporting system is significant. Here is what genuinely matters:

Evaluation Criterion

Why It Matters

Vendor neutrality

Labs use equipment from multiple manufacturers. Tied software restricts procurement freedom.

ATS-aligned reporting

Ensures clinical outputs meet internationally recognised guidelines.

Normal values library

Must be regularly updated and configurable to patient demographics.

EMR and PAS integration

Eliminates double data entry, a key source of clinical risk.

Cloud vs. on-premise

Cloud reduces IT overhead; on-premise may suit specific Trust security requirements.

Accreditation support

ISO 15189, TSANZ/NATA-aligned modules reduce audit preparation burden.

Sleep module depth

Many platforms treat sleep as an add-on. It should be a core, not a bolt-on.

Data migration pathway

Moving from a legacy system should not require months of manual re-entry.

Roche's Lab Leaders resource notes that laboratory innovation increasingly depends on systems that reduce manual processes and support clinician decision-making, a principle that applies directly to respiratory lab software selection.

What Are the Main Categories of Vendor in This Market?

The UK respiratory lab software landscape in 2026 broadly falls into four categories:

1. Device Manufacturer Software
Platforms bundled with spirometry or sleep diagnostic hardware. Convenient at point of purchase, but typically locked to that manufacturer's devices. Problematic when labs need to use equipment from multiple vendors or when device contracts change.

2. Generic LIMS or EPR Modules
Large hospital EPR systems sometimes include respiratory modules. These are rarely built with clinical physiology workflows in mind and often require significant customisation to handle flow-volume loops, sleep staging, or normal values calculations.

3. Legacy Standalone Systems
Installed software that has been in use for many years, sometimes decades. Often reliable but increasingly difficult to maintain, not cloud-compatible, and poorly suited to modern integration requirements.

4. Purpose-Built Independent Platforms
The smallest category, and the most clinically relevant. These are systems built specifically for respiratory and sleep labs, by people with domain expertise, and designed to be device-agnostic from the ground up.

Rezibase sits firmly in this fourth category. Founded by respiratory scientists Peter Rochford and the late Jeff Pretto, the platform was built to solve the specific frustrations of clinical physiology labs: clunky interfaces, vendor lock-in, and systems that could not keep up with evolving standards.

How Does Vendor Lock-In Affect NHS Procurement?

Vendor lock-in in respiratory lab software typically manifests in two ways: device dependency and data portability. When software is tied to a specific manufacturer's hardware, the lab loses negotiating power on equipment renewals. When data cannot be easily exported in structured formats, switching platforms becomes disproportionately costly.

The digital respiratory devices market is evolving rapidly, as noted in a February 2026 analysis from OpenPR, which highlights major growth opportunities alongside challenges in interoperability and integration. For NHS Trusts, this underscores the importance of selecting platforms that are built for integration, not isolation.

Rezibase addresses this directly through its Magic Import function, which allows data from any device manufacturer to be imported and processed within the same platform, extracting discrete data including flow-volume loops automatically.

Is Switching from a Legacy System Actually Complicated?

This is the question that most delays procurement decisions, and the honest answer is: it depends almost entirely on the platform you are switching to.

Labs running older systems such as Respiro often worry about data loss or prolonged downtime. In practice, structured migration pathways make the transition manageable. Key factors that simplify the process include:

  • Platforms that accept structured data imports from legacy formats

  • Vendors with direct experience migrating from specific legacy systems

  • Cloud-based architecture that does not require parallel server infrastructure during transition

  • Clear project management support from the vendor

Rezibase has direct experience supporting transitions from legacy respiratory platforms and is designed to make the switchover as straightforward as possible, with data migration handled as part of the onboarding process.

Frequently Asked Questions

Is Rezibase available to NHS Trusts in the UK?
Yes. Rezibase is already active within NHS Trusts in the UK and is designed to integrate with NHS PAS and EMR systems.

Does Rezibase support both respiratory and sleep reporting in one platform?
Yes. Both are core modules, not add-ons. Sleep reporting is treated with the same depth as respiratory function testing.

What normal values does Rezibase use?
The platform includes a pre-configured, regularly updated library of industry-standard normal values, configurable to patient demographics.

How long does implementation typically take?
Implementation timelines vary by Trust size and integration complexity, but Rezibase's cloud-based architecture removes the server provisioning delays common with on-premise deployments.

Can we trial Rezibase before committing?
Yes. Rezibase offers a 30-day free trial with no lock-in contracts and transparent all-inclusive monthly pricing.

What accreditation standards does the platform support?
Rezibase includes an accreditation module aligned to ISO 15189 requirements, covering documents, training, non-conformance, action plans, audits, and quality control.

Is Rezibase suitable for both NHS and private labs?
Yes. The platform serves public hospital labs and private respiratory and sleep clinics across the UK, Australia, New Zealand, and Ireland.

About Rezibase

Rezibase is a cloud-based respiratory and sleep reporting platform built by respiratory scientists for respiratory scientists, currently trusted by over 35 sites including NHS Trusts in the UK and NSW Health in Australia. Developed with a vendor-neutral philosophy, it covers the full clinical and administrative lifecycle of a respiratory or sleep lab, from referrals and bookings through to accreditation management and integrated reporting. Rezibase is a product of Cardiobase, a healthcare technology company with 37 years of experience in clinical diagnostics software.

Explore Rezibase for your NHS Trust at rezibase.com.

References

Automating Post-Test Patient Communication and Follow-Up Scheduling: Closing the Loop Between Lab Results and Clinical Action ›

Automating Post-Test Patient Communication and Follow-Up Scheduling: Closing the Loop Between Lab Results and Clinical Action ›